Gonçalves, João Manuel BrazFerro, Luís Filipe Pomares2021-01-292021-01-292013-12-092013http://hdl.handle.net/10451/46026Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2013Currently, there are five anti-tumour necrosis factor alpha (TNF-α) drugs licensed for the use in treatment in rheumatoid arthristis (RA): Infliximab (Remicade®), Etanercept (Embrel®), Adalimumb (Humira®), Certolizumab (Cimza®) and Golimumab (Simponi®). The formation of anti-drug antibodies (ADA) has been demonstrated for all the five agents and its implications in clinical efficacy has been on the agenda lately. Since there are no significant difference in clinical trials in short-term drug efficacy, protection from radiographic damage or side-effect profiles, immunogenicity could bring light to this field and help us to compare directly the five molecules. We intend to analyze the available work in what immunogenicity is concerned for each protein, trying to establish a direct comparison between the drugs and point out the limitations and unmet needs in this area.enganti-TNF-α;anti-drug-antibodiesImmunogenicityImplicationsMestrado Integrado - 2013master thesis